Ibrance (palbociclib) - Pfizer
Ibrance: Data from P3 PALLAS trial (NCT02513394) for HR+/HER2- breast cancer in H2 2020 (Pfizer) - Apr 30, 2019 - Q1 2019 Results: Data from P3 PENELOPE-B trial (NCT01864746) for breast cancer in H2 2020 
P3 data
https://investors.pfizer.com/investors-overview/default.aspx
 
Apr 30, 2019
 
 
925037ec-5108-4a1f-a936-5c56744d8bcc.jpg